Study of disulfiram for vision in retinal degeneration
Part of Eyes & vision, Genetic & congenital, Mental health clinical trials.
This trial tests whether disulfiram, a drug used for alcohol use disorder, can improve vision in people with retinal degeneration. You must have an alcohol use diagnosis and agree to avoid alcohol for 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an inherited retinal disease or dry age-related macular degeneration.
- You have a diagnosis of alcohol use disorder and are a candidate for disulfiram therapy.
- You agree to avoid all alcohol for 180 days.
- You have vision ranging from 20/20 to light perception in your better eye.
- You can take oral medication and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will check if certain vision tests work well in people with retinal diseases like retinitis pigmentosa or Stargardt. Results will help design future trials.
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
This study tests whether a medication called disulfiram (Antabuse) can help people with alcohol use disorder (AUD) feel less anxious when they stop drinking. Researchers will also use brain scans (MRI) to look at how the brain changes during early abstinence.
This trial tests an algae-derived powder taken by mouth to see if it can improve visual function in teenagers with retinitis pigmentosa. Because it’s early-stage, it focuses on safety and early signs of benefit to vision tests.
This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.
Hear when a new Alcohol Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.